Key Takeaways CMS has prohibited Medicaid and CHIP reimbursement for certain types of gender-affirming healthcare for minors, including puberty blockers, cross-sex hormone therapy and surgical intervention, effective October 13, 2026. The Final Rule’s prohibitions only apply if the purpose of treatment is gender-affirming healthcare. Federal funds remain available for the same drugs and therapies when … Continued
| less than a minute read
CMS Imposes Prohibition on Federal Medicaid and CHIP Payment for Certain Gender-Affirming Healthcare for Minors: What Providers Need to Know

/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-11-18-14-13-10-258-6afdb276fe780fcb4c51df13.jpg)
/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-11-18-14-12-06-611-6afdb23653016789c4056cea.jpg)
/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-11-17-18-06-10-408-6afc9792452800fa09ad0765.jpg)
